Breaking News Instant updates and real-time market news.

SELB

Selecta Biosciences

$2.49

-0.07 (-2.73%)

16:10
04/16/19
04/16
16:10
04/16/19
16:10

Selecta Biosciences to present AAV-based gene therapy vectors data at ASGCT

Selecta Biosciences announced that five presentations of new preclinical data demonstrating the potential for the re-dosing of adeno-associated virus, or AAV-based, gene therapy vectors when administered in combination with its ImmTOR platform will be presented by Selecta scientists and collaborators from the National Institutes of Health and the International Centre for Genetic Engineering and Biotechnology, or ICGEB, at the upcoming American Society of Gene and Cell Therapy, or ASGCT. In naive mice models, co-administration of ImmTOR and AAV-based vectors enhanced transgene expression after the first dose of AAV vector, with rapid and enhanced transgene expression, which may enable therapeutic benefit at lower doses, potentially avoiding toxicities associated with larger doses. In a mouse model of Ornithine TransCarbamylase deficiency, a monogenic urea cycle disease that results in the accumulation of ammonia in the blood, ssAAV8-OTC in combination with ImmTOR was shown to effectively restore the physiological levels of urinary orotic acid and serum ammonia, correcting disease. These data demonstrate a new opportunity to treat pediatric patients with the possibility to re-dose to maintain therapeutic levels. Using a murine passive antibody transfer mouse model, the addition ImmTOR to Anc80-Mut enabled transgene expression even in the presence of moderately neutralizing antibodies against the Anc80 AAV vector. In a mouse model of the severe childhood form of isolated MMA, ImmTOR treatment was well tolerated and enabled repeat dosing of Anc80-Mut vector. A survey of sera from Mut-deficient MMA patients showed only 2/27 patients were seropositive for neutralizing antibodies, or NAb, against the Anc80 vector. The low seroprevalence of pre-existing Anc80 NAbs in the MMA patient population, and the ability to mitigate formation of new NAbs with ImmTOR, has the potential to make this combination therapy versatile and amenable for repeat dosing.

SELB Selecta Biosciences
$2.49

-0.07 (-2.73%)

10/23/18
STFL
10/23/18
NO CHANGE
STFL
Buy
Selecta SEL-212 data 'very competitive to Krystexxa mono/combo therapy, says Stifel
Stifel analyst Derek Archila views Selecta Biosciences (SELB) SEL-212 Phase 2 data in chronic severe gout as positive and thinks it represents a "very competitive" emerging profile relative to the incumbent brand, Horizon Pharma's (HZNP) Krystexxa. The analyst comes away positive with the fact SEL-212's projected response rate remains competitive on a modified intent-to-treat basis, SVP-Rapamycin was tolerable out to five months of dosing, and SEL-212's rate of gout flares was lower than Krystexxa alone and Krystexxa+methotrexate early on. Archila remains positive on the stock and believes SEL-212 could offer an improvement to the current standard of care for chronic severe gout. Further, Archila does not believe shares fully reflect the program's commercial potential and reiterates a Buy rating on Selecta's shares.
01/28/19
NEED
01/28/19
NO CHANGE
Target $12
NEED
Buy
Selecta Biosciences price target lowered to $12 from $28 at Needham
Needham analyst Chad Messer lowered his price target on Selecta Biosciences to $12 to reflect the impact of equity dilution from the company's recent financing and also the longer timeframe for the launch of its SEL-212 product. Longer term, the analyst keeps his Buy rating on Selecta Biosciences based on the potential for SEL-212 to succeed in clinical trials for refractory and tophaceous gout and for its possibility of "bringing additional SVP programs to the clinic."
02/04/19
MZHO
02/04/19
NO CHANGE
Target $4
MZHO
Buy
Selecta Biosciences price target lowered to $4 from $19 at Mizuho
Mizuho analyst Difei Yang lowered her price target for Selecta Biosciences to $4 following the company's "dilutive" capital raise on January 23. Selecta's cash runway is expected to be into Q2 of 2020 and should be sufficient to support the head-to-head phase 2 trial of SEL-212 versus Krystexxa, Yang tells investors in a research note. The analyst continues to see "significant value" in SEL-212 and believes results from the head-to-head trial could be the next key catalyst. However, additional capital is likely needed for the Phase III trials, she adds. Yang keeps a Buy rating on Selecta Biosciences.
03/18/19
ADAM
03/18/19
NO CHANGE
Target $13
ADAM
Buy
Selecta Biosciences price target cut to $13 from $25 at Canaccord
Canaccord analyst John Newman maintained a Buy rating on Selecta Biosciences and cut his price target to $13 from $25, telling investors that he is still "positive" on SEL-212, but is awaiting validating data from the COMPARE trial, which he says would reduce risk and provide a solid superiority to compare SEL-212 with its closest competitor, Krystexxa. Newman notes that the Phase 2 SEL-212 results did not clearly demonstrate the benefit he was expecting due to study design reasons, and is lowering the probabilyt of success to 60% from 80% and lowered his SEL-212 peak estimated U.S. sales to $750M from $1.2B in 2028.

TODAY'S FREE FLY STORIES

NSRGY

Nestle

$0.00

(0.00%)

06:25
04/18/19
04/18
06:25
04/18/19
06:25
Earnings
Nestle reports 3-month reported sales CHF22.18B vs. CHF21.264B last year »

Organic growth was 3.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NINE

Nine Energy Services

$21.10

-0.34 (-1.59%)

06:24
04/18/19
04/18
06:24
04/18/19
06:24
Conference/Events
Nine Energy Services management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 07

    May

  • 08

    May

ACRGF

Acreage Holdings

$0.00

(0.00%)

06:24
04/18/19
04/18
06:24
04/18/19
06:24
Hot Stocks
Acreage Holdings to acquire Deep Roots Medical for $120M in common units, cash »

Acreage Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

MU

Micron

$43.16

0.34 (0.79%)

06:23
04/18/19
04/18
06:23
04/18/19
06:23
Conference/Events
Micron management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

TSM

TSMC

$44.37

1.17 (2.71%)

06:22
04/18/19
04/18
06:22
04/18/19
06:22
Earnings
TSMC sees Q2 revenue $7.55B-$7.65B, consensus $7.83B »

Gross profit margin is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

TSM

TSMC

$44.37

1.17 (2.71%)

06:22
04/18/19
04/18
06:22
04/18/19
06:22
Earnings
TSMC reports Q1 EPS 38c, consensus 37c »

Reports Q1 revenue $7.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

ASOMY

Asos

$0.00

(0.00%)

06:21
04/18/19
04/18
06:21
04/18/19
06:21
Conference/Events
Asos management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 23

    Apr

GOOG

Alphabet

$1,235.76

8.7 (0.71%)

, GOOGL

Alphabet Class A

$1,240.35

8.44 (0.69%)

06:20
04/18/19
04/18
06:20
04/18/19
06:20
Periodicals
Measles hits Google's Silicon Valley headquarters, BuzzFeed reports »

A Google employee who had…

GOOG

Alphabet

$1,235.76

8.7 (0.71%)

GOOGL

Alphabet Class A

$1,240.35

8.44 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 29

    Apr

  • 14

    May

  • 27

    Oct

FMC

FMC Corporation

$80.75

0.01 (0.01%)

06:18
04/18/19
04/18
06:18
04/18/19
06:18
Downgrade
FMC Corporation rating change  »

FMC Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 30

    Apr

  • 07

    May

  • 22

    May

  • 23

    May

ECL

Ecolab

$182.95

-2.41 (-1.30%)

06:18
04/18/19
04/18
06:18
04/18/19
06:18
Downgrade
Ecolab rating change  »

Ecolab downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 02

    May

  • 18

    May

  • 29

    May

  • 05

    Jun

CRM

Salesforce

$155.31

-3.37 (-2.12%)

06:17
04/18/19
04/18
06:17
04/18/19
06:17
Hot Stocks
Salesforce agrees to acquire MapAnything; financial terms not disclosed »

Salesforce announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

FB

Facebook

$178.77

-0.13 (-0.07%)

06:15
04/18/19
04/18
06:15
04/18/19
06:15
Periodicals
Facebook 'unintentionally' uploaded email contacts of 1.5M users, BI reports »

Facebook has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

MSFT

Microsoft

$121.75

1.09 (0.90%)

06:14
04/18/19
04/18
06:14
04/18/19
06:14
Periodicals
Microsoft rejects facial-recognition sale on human rights concerns, Reuters says »

Microsoft recently denied…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 23

    Jun

  • 06

    Aug

NOW

ServiceNow

$236.15

-3.65 (-1.52%)

, ZEN

Zendesk

$80.79

-1.17 (-1.43%)

06:14
04/18/19
04/18
06:14
04/18/19
06:14
Recommendations
ServiceNow, Zendesk, LogMeln analyst commentary at Piper Jaffray »

ServiceNow price target…

NOW

ServiceNow

$236.15

-3.65 (-1.52%)

ZEN

Zendesk

$80.79

-1.17 (-1.43%)

LOGM

LogMeln

$81.22

-0.74 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 30

    Apr

  • 28

    May

  • 05

    Jun

  • 06

    Jun

  • 13

    Nov

FB

Facebook

$178.77

-0.13 (-0.07%)

, AMZN

Amazon.com

$1,864.63

3.63 (0.20%)

06:12
04/18/19
04/18
06:12
04/18/19
06:12
Periodicals
Facebook confirms work on voice, AI assistant technologies, Reuters reports »

A Facebook spokesperson…

FB

Facebook

$178.77

-0.13 (-0.07%)

AMZN

Amazon.com

$1,864.63

3.63 (0.20%)

AAPL

Apple

$203.14

4.14 (2.08%)

MSFT

Microsoft

$121.75

1.09 (0.90%)

GOOG

Alphabet

$1,235.76

8.7 (0.71%)

GOOGL

Alphabet Class A

$1,240.35

8.44 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 10

    May

  • 14

    May

  • 03

    Jun

  • 23

    Jun

  • 06

    Aug

  • 27

    Oct

GBX

Greenbrier

$33.37

0.12 (0.36%)

06:11
04/18/19
04/18
06:11
04/18/19
06:11
Hot Stocks
Greenbrier to acquire manufacturing business of American Railcar »

Greenbrier announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

STI

SunTrust

$63.77

0.475 (0.75%)

06:11
04/18/19
04/18
06:11
04/18/19
06:11
Earnings
SunTrust reports Q1 EPS $1.24, consensus $1.30 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 23

    Apr

  • 29

    May

UAA

Under Armour

$21.94

0.14 (0.64%)

, UA

Under Armour

$19.66

0.19 (0.98%)

06:10
04/18/19
04/18
06:10
04/18/19
06:10
Recommendations
Under Armour, Under Armour, Nike, Adidas analyst commentary at Piper Jaffray »

Under Armour Q1…

UAA

Under Armour

$21.94

0.14 (0.64%)

UA

Under Armour

$19.66

0.19 (0.98%)

NKE

Nike

$88.74

0.84 (0.96%)

ADDYY

Adidas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 09

    May

PEP

PepsiCo

$127.05

4.55 (3.71%)

06:09
04/18/19
04/18
06:09
04/18/19
06:09
Upgrade
PepsiCo rating change  »

PepsiCo upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 18

    May

NMIH

NMI Holdings

$27.08

-0.25 (-0.91%)

06:09
04/18/19
04/18
06:09
04/18/19
06:09
Initiation
NMI Holdings initiated  »

NMI Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 09

    May

TRX

Tanzanian Royalty

$0.81

0.039 (5.06%)

06:08
04/18/19
04/18
06:08
04/18/19
06:08
Syndicate
Tanzanian Royalty announces sale of $350,000 of common shares »

Tanzanian Gold's,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROW

T. Rowe Price

$106.15

-0.54 (-0.51%)

, TSLA

Tesla

$271.12

-1.38 (-0.51%)

06:08
04/18/19
04/18
06:08
04/18/19
06:08
Periodicals
T. Rowe Price funds cut Tesla holdings in Q1, Reuters reports »

T. Rowe Price (TROW)…

TROW

T. Rowe Price

$106.15

-0.54 (-0.51%)

TSLA

Tesla

$271.12

-1.38 (-0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

  • 25

    Apr

ENV

Envestnet

$69.17

-0.39 (-0.56%)

06:07
04/18/19
04/18
06:07
04/18/19
06:07
Initiation
Envestnet initiated  »

Envestnet initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 05

    Jun

GTLS

Chart Industries

$88.07

1.13 (1.30%)

06:07
04/18/19
04/18
06:07
04/18/19
06:07
Earnings
Chart Industries raises FY19 adjusted EPS view to $2.70-$3.05 from $2.50-$2.85 »

Consensus for FY19 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 28

    May

  • 05

    Jun

BA

Boeing

$377.54

-3.96 (-1.04%)

06:06
04/18/19
04/18
06:06
04/18/19
06:06
Hot Stocks
Boeing making 'steady progress' on path to 737 MAX software certification »

Boeing is making…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 29

    Apr

  • 29

    May

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.